
Alessandro Riva joined Transgene in 2022 as Chairman of the Board of Directors and became Chief Executive Officer in 2023. He brings nearly 30 years’ experience in the Life Sciences industry, in pharmaceutical and biotech companies.
He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and CEO of Ichnos Sciences. Alessandro Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma. Prior to Gilead, Alessandro Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals. Alessandro Riva currently serves on the Boards of BeOne and Century Therapeutics.
He received his bachelor’s degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.

Katell Bidet Huang is the head of Translational Medicine at Transgene, where she focuses on characterizing the immune responses after treatment with viral-vectored individualized cancer vaccine and oncolytic viruses. She has a scientific background in virology and immunology and a particular interest in understanding how and why patients respond to therapy. Prior to Transgene, she was head of Translational Research at Hookipa Pharma and Biomarker Scientist at Curevac. She obtained her PhD in molecular virology from the National University of Singapore and did her post-doctoral training at the Singapore-MIT Alliance for Research and Technology on dengue vaccine development.

Emmanuelle Dochy, MD, joined Transgene in September 2024 as Chief Medical Officer (CMO).
Emmanuelle Dochy, MD, has served Transgene as Chief Medical Officer (VP Medical and Regulatory Affairs) since 2024. Emmanuelle Dochy was previously Vice President of Global Medical Affairs at Bayer, where she gained extensive experience in managing medical affairs on a global scale. With 15 years of experience in the pharmaceutical industry, she has held a variety of medical affairs, various strategic positions, focusing particularly on managing clinical trials from preclinical stages through advanced development.
Emmanuelle began her career at Sanofi Belgium, where she was responsible for Oncology. Among her notable achievements, she led the European launch of aflibercept for metastatic colorectal cancer and contributed to the development and submission of post-marketing approval files, particularly for new indications of docetaxel in the treatment of prostate cancer. Emmanuelle Dochy holds a medical degree from the Université Libre de Bruxelles and is specialized in Internal Medicine.

John Felitti has served Transgene as General Counsel & Corporate Secretary since 2016. Before joining Transgene, he was Associate Vice President, Corporate Law, Finance & Securities Law at Sanofi and previously held other positions in the Sanofi and the Aventis legal departments. From 1996 to 2003, he was an associate attorney at the Paris offices of the global U.S. law firm Shearman & Sterling. He is admitted to practice in New York and is a former member of the Paris Bar.
After majoring in economics at Harvard University (AB 1991) and the College of Europe (MA 1993), John Felitti studied law at the University of Michigan (JD 1996) and the University of Paris II – Panthéon (LLM 1997). He also holds a business degree from INSEAD (GEMBA 2015).

Lucie Larguier has served as Chief Financial Officer since 2024. From 2016 to 2023, Lucie had served the Company as Director Corporate Communications and Investor Relations, reporting to the CEO. She joined the Executive Comity in 2023 as VP, Corporate Communication and Investor Relations. Specialist in financial communications and press relations, Lucie spent over 10 years’ in corporate and financial communications agencies advising private and listed companies, as well as a variety of financial institutions.
She is a graduate of Paris Institute of Political Studies (Sciences Po), with a Master’s degree in communication and a specialization in finance.

Christelle Schwoerer has served as VP Human Resources since 2024.
She joined Transgene’s Human Resources department in December 2013 as a Human Resources Assistant, after initial experience in construction and industry.
Her various roles at Transgene have enabled her to develop generalist skills in human resources and to contribute to projects of major importance to the company. Her knowledge of the organization, its culture and its employees are real assets in her new missions.
Christelle Schwoerer holds a Master 1 Ressources Humaines from the CNAM Grand-Est and a Master 2 Management – Ressources Humaines from the Ecole de Management de Strasbourg, obtained in 2020 and 2021.

Anne Stehlin, PharmD, recently joined Transgene as Chief Quality Officer and Responsible Pharmacist. Dr. Stehlin is a pharmaceutical executive with extensive experience in quality and manufacturing operations.
Prior to joining Transgene, she held senior global quality leadership roles at Lonza, a leading biopharmaceutical CDMO. Before that, she served as Head of Global Quality Management and a member of the extended management team at Basilea Pharmaceutica.
Earlier in her career, she held multiple leadership roles at Novartis across technical operations and product quality, eventually serving as Global Head of Product Quality Lifecycle Management. Dr. Stehlin holds a PharmD degree from the University of Strasbourg.

Simone Steiner serves as Chief of Technical Officer since 2025. Dr. Simone Steiner, PhD is a Senior Executive and Board Advisor with almost 20 years of pharma experience across preclinical, clinical and commercialization gained within organizations ranging from startups to multinational Pharma companies. Prior to joining Transgene, she was the Chief Technical Operating Officer (CTOO) at T-knife Therapeutics, a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, where she led technical development and manufacturing.
Before her time at T-knife, Dr. Steiner was Head of Technical Development and Manufacturing at Tigen, in Switzerland, where she managed the optimization of manufacturing processes and the creation of new biopharmaceutical products. Dr. Steiner’s career also includes over ten years at Novartis, where she expanded her expertise in technical operations and manufacturing, contributing to large-scale production strategies for groundbreaking therapies. With a strong foundation in cutting-edge technologies and their implications for health, Dr. Steiner is recognized for combining scientific precision with strategic management to advance therapeutic development and manufacturing initiatives. She served as a Scientific Advisor at NegotiumAI, an innovative platform leveraging state-of-the-art AI to streamline the relationship between advanced therapy drug developers and contract manufacturers.
Dr. Steiner holds a Master’s in Biochemistry, a PhD from ETH Zurich and completed a postdoctoral fellowship at the University of Alberta, Canada.

James Wentworth, PhD, has serve as Chief Business Officer since 2024. Dr. Wentworth is responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategies.
He has over 15 years of experience working in the pharma and biotech industry. James was Director, Business Development and Strategy at Adaptimmune, a NASDAQ-listed biotechnology company focused on developing T-cell receptor (TCR)-based cell therapies for solid tumors. His responsibilities included strategic pharma partnering, collaborations and transactions, corporate development projects, commercial strategy development and he also led the company’s competitive intelligence function. Prior to Adaptimmune, James worked with precommercial Biotech companies at inVentiv Health (now Syneos Health) and held strategic roles at Shire, contributing to product development, post M&A integration, and managing commercial launches in European markets for ViroPharma Europe.
James holds a BSc Hons degree in Pharmacology and a PhD in Pharmacology both from the University of Bristol and an MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland.
Last update : March 2026.